Mita Kuchimanchi

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

John P. Gibbs, Sameer Doshi, Mita Kuchimanchi et al. · The Journal of Clinical Pharmacology · 2016 · 42 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain

Mita Kuchimanchi, Michael Monine, Kumar Kandadi Muralidharan et al. · CPT Pharmacometrics & Systems Pharmacology · 2020 · 38 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

Jianfeng Lü, Erik Rasmussen, Beth Y. Karlan et al. · Cancer Chemotherapy and Pharmacology · 2011 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis

Ping Chen, Murad Melhem, Jim Xiao et al. · The Journal of Clinical Pharmacology · 2015 · 31 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients

Jianfeng Lü, Laurent Claret, Liviawati Sutjandra et al. · Cancer Chemotherapy and Pharmacology · 2010 · 28 citations

Medicine, Oncology, Pharmacology +16